(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 43.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Iovance Biotherapeutics's revenue in 2025 is $241,525,000.On average, 5 Wall Street analysts forecast IOVA's revenue for 2025 to be $101,211,982,127, with the lowest IOVA revenue forecast at $92,536,896,824, and the highest IOVA revenue forecast at $108,700,910,358. On average, 5 Wall Street analysts forecast IOVA's revenue for 2026 to be $178,259,361,079, with the lowest IOVA revenue forecast at $162,834,253,200, and the highest IOVA revenue forecast at $195,545,845,398.
In 2027, IOVA is forecast to generate $258,481,284,260 in revenue, with the lowest revenue forecast at $224,349,415,520 and the highest revenue forecast at $307,282,709,944.